FLVCR1: A Potential Drug Target for Feline Leukemia Virus (G28982)

Target Name: FLVCR1

NCBI ID: G28982

FLVCR1

FLVCR1: A Potential Drug Target for Feline Leukemia Virus

FLVCR1, also known as Feline Leukemia Virus Subgroup C Receptor, is a protein that is expressed in the surface of feline leukemia virus (FLV) particles. It is a member of the immunoglobulin (Ig) family and is responsible for the recognition of certain viruses, including FLV.

FLVCR1 is a critical receptor for the virus to infect feline cells. It is expressed in the cells that are infected by the virus, and it is involved in the process of virus replication. Studies have shown that FLVCR1 plays a crucial role in the development and progression of FLV disease in felines.

FLVCR1 is also a potential drug target for human diseases. Its functions in the immune system and its unique structure have led researchers to believe that it may be a useful target for new treatments.

One of the main advantages of FLVCR1 as a drug target is its expression in the immune system. It is highly expressed in the spleen, lymph nodes, and bone marrow, which are all sites of immune response. This makes it an attractive target for drugs that can inhibit its activity and reduce the immune response to the virus.

Another potential advantage of FLVCR1 is its unique structure. It is a type of protein that is composed of multiple domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. This structure allows it to interact with other proteins in the cell and to have a variety of different functions.

Research has shown that FLVCR1 plays a role in the development and progression of several human diseases, including cancer, autoimmune diseases, and neurodegenerative diseases. For example, studies have shown that FLVCR1 is highly expressed in the spleen and lymph nodes of people with B- cell malignancies, such as leukemia and lymphoma. This suggests that FLVCR1 may be a useful biomarker for these diseases and that targeting its activity may be a promising new approach to treatment.

Targeting FLVCR1 may also be a useful approach to treating other human diseases that are caused by the immune system. For example, FLVCR1 has been shown to be involved in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By targeting its activity , researchers may be able to develop new treatments for these diseases.

In conclusion, FLVCR1 is a protein that is expressed in the surface of feline leukemia virus particles and is involved in the process of virus replication and the development and progression of FLV disease in felines. It is also a potential drug target for human diseases due to its expression in the immune system and unique structure. Further research is needed to fully understand its functions and to develop new treatments for FLV disease and related human diseases.

Protein Name: FLVCR Heme Transporter 1

Functions: Heme transporter that exports cytoplasmic heme. Heme export depends on the presence of HPX and is required to maintain intracellular free heme balance, protecting cells from heme toxicity. Heme export provides protection from heme or ferrous iron toxicities in liver, brain, sensory neurons and during erythropoiesis, a process in which heme synthesis intensifies. Possibly export coproporphyrin and protoporphyrin IX, which are both intermediate products in the heme biosynthetic pathway. Does not export bilirubin

The "FLVCR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLVCR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets